StockWatch
·
Pharmaceuticals
USFDA14 Nov 2026, 05:06 pm

Dr Reddy's USFDA Inspection Closed as Voluntary Action Indicated

AI Summary

Dr Reddy's Laboratories Ltd has announced that the United States Food & Drug Administration (USFDA) has concluded its inspection of the company's formulations manufacturing facility (FTO-3) in Bachupally, Hyderabad. The inspection, initially disclosed on August 14, 2026, has been classified as 'Voluntary Action Indicated (VAI)'. The USFDA has officially closed the inspection under 21 CFR 20.64(d)(3), indicating a satisfactory outcome with no major compliance issues requiring immediate mandatory action.

Key Highlights

  • USFDA inspection at Bachupally facility concluded.
  • Inspection outcome classified as Voluntary Action Indicated (VAI).
  • USFDA officially closed the inspection.
  • No major compliance issues identified by the regulator.